Literature DB >> 2893038

Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.

.   

Abstract

144 patients presenting within 4 h of onset of myocardial infarction were randomised to receive either 100 mg of single-strand recombinant tissue plasminogen activator (rTPA) in 3 h (n = 73) or placebo infused at the same rate (n = 71). All patients were given heparin 5000 units before the infusion and heparin was continued, initially at 1000 units per hour, after the infusion. Minor bleeding was more frequent in the rTPA recipients, and during subsequent anticoagulant therapy there were three clinically significant bleeding episodes in this group. Patency of the infarct-related coronary artery was determined by coronary angiography about one week post-infarction, 125 angiograms being assessable. The infarct-related artery was patent in 70% of patients who received rTPA and in 41% of those who did not (p = 0.0015). In the 103 patients who had assessable contrast ventriculograms, the global ejection fractions were 57.7% and 51.7%, respectively (p = 0.04). The difference in ventricular function was largest in patients with anterior infarction (52.7% versus 40.0%, p = 0.02). The magnitude of these changes suggests an improvement in ejection fraction of 12% overall and about 30% in patients with anterior infarction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2893038

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  7 in total

1.  Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Assessment of reperfusion after acute myocardial infarction: is there a role for acute technetium 99m-teboroxime imaging?

Authors:  A J Sinusas
Journal:  J Nucl Cardiol       Date:  1996 Jan-Feb       Impact factor: 5.952

Review 3.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 4.  Thrombolytic therapy. From myocardial to cerebral infarction. The MAST-I Group. Multicentre Acute Stroke Trial.

Authors:  L Candelise; C Roncaglioni; E Aritzu; A Ciccone; A P Maggioni
Journal:  Ital J Neurol Sci       Date:  1996-02

Review 5.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  Low-molecular-weight heparins in acute myocardial infarction: rationale and results of a pilot study.

Authors:  A M Ross; K Coyne; M Hammond; C F Lundergan
Journal:  Clin Cardiol       Date:  2000-07       Impact factor: 2.882

Review 7.  Comparative tolerability profiles of thrombolytic agents. A review.

Authors:  K S Woo; H D White
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.